Compare AbCellera Biologics Inc (ABCL) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs YieldMax AMZN Option Income Strategy ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while YieldMax AMZN Option Income Strategy ETF trades at $10.68. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | AMZY | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $8.12 | $16.61 |
52-Week Low | $2.78 | $10.26 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AMZY trades at $10.74, up 0.51% today, with a bearish technical signal from moving averages. The ETF generates high weekly dividends but faces scrutiny over net asset value erosion. Recent news highlights consistent distribution announcements alongside analyst downgrades citing structural risks in its synthetic option strategy relative to Amazon's performance.
The outlook is cautious due to inevitable NAV erosion despite high yield, with total returns lagging Amazon. Risks include amplified downside exposure and unsustainable payouts. Investors prioritizing income may find appeal, but long-term capital appreciation appears constrained by the fund's design.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →
